NurExone logo2.png
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application
11 juin 2024 08h44 HE | NurExone Biologic Inc
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application
download.png
NurExone Announces Q4 and Full-year 2022 Financial Results and Provides Company Update, Highlighting 143.9% Scientific Research Investment Growth
30 mars 2023 08h40 HE | NurExone
TORONTO and TEL AVIV, Israel, March 30, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (the "Company" or "NurExone") (TSXV: NRX) (FSE: J90) (NRX.V), a biopharmaceutical company developing...
Stress levels in treated rats (as indicated by self-harm)
NurExone Biologic Reports Additional Positive Preclinical Trial Outcomes with ExoPTEN: 75% of Paralyzed Rats Show Recovery after Acute Spinal Cord Injury Study
20 mars 2023 07h58 HE | NurExone
TORONTO and TEL AVIV, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Toronto and Tel Aviv, March 20, 2023 - Biopharmaceutical firm NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (“NurExone” or...
PR Scientific  160223 Figure 1.jpg
NurExone Announces Interim Positive Results of Internal Preclinical Study of Proprietary ExoPTEN Drug
17 févr. 2023 08h00 HE | NurExone
TORONTO and HAIFA, Israel, Feb. 17, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V), a biopharmaceutical company developing biologically-guided exosome therapy...